Cervical Cancer (MSK, Clin Cancer Res 2023)

Summary

Cervical Cancer (MSK, Clin Cancer Res 2023) is a study catalogued by cBioPortal DataHub under the cancer-type code cervix. EvidenceHelix groups it with gynecologic studies.

Study description

Targeted sequencing of 177 cervical tumors and their matched normal samples via MSK-IMPACT.

Text as published in the source's study metadata.

Citation & PubMed

Friedman et al. Clin Cancer Res 2023

Linked PubMed records: PMID 37643132

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

cervix_msk_2023

Short name

not given

Source cancer-type code

cervix

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Friedman et al. Clin Cancer Res 2023

• PubMed record 37643132 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Endometrial and Ovarian Cancer (MSK, Nature Medicine 2024)

  Targeted sequencing of 33 endometrial and ovarian tumors and their matched normals via MSK-IMPACT.

  GynecologicMSK studiesSource code mixedPubMed 1

• Endometrial Cancer (MSK, 2018)

  MSK-IMPACT sequencing of 197 advanced-staged endometrial cancer tumor samples with matched normals, from 189 patients treated at MSK.

  GynecologicMSK studiesSource code ucecPubMed 1

• Endometrial Cancer (MSK, Cancer Discovery 2023)

  Targeted sequencing of 1882 endometrial cancers and their matched normals via MSK-IMPACT.

  GynecologicMSK studiesSource code ucecPubMed 1

• Endometrial Carcinoma (MSK, Molecular Oncology 2024)

  Targeted sequencing of 69 ERBB2-mutant endometrial carcinoma tumors and their matched normal pairs via MSK-IMPACT.

  GynecologicMSK studiesSource code ucecPubMed 1

• Endometrial Carcinoma cfDNA (MSK, Clin Cancer Res 2022)

  High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer.

  GynecologicMSK studiesSource code ucecPubMed 1

• Endometrial Carcinoma MSI (MSK, Clin Cancer Res 2022)

  Clinical and genetic features of microsatellite instability-high endometrial cancers harboring germline or somatic mutations in MMR genes or MLH1 promoter hypermethylation.

  GynecologicMSK studiesSource code ucecPubMed 1

• High-Grade Serous Ovarian Cancer (MSK, NPJ Genome Med 2021)

  Targeted Sequencing of 45 Serous Ovarian Cancer tumor/normal pairs from 45 patients.

  GynecologicMSK studiesSource code hgsocPubMed 1

• Low-Grade Serous Ovarian Cancer (MSK, Clin Cancer Res 2022)

  Characterization of the somatic mutational landscape of MAPK pathway in 119 low-grade serous ovarian carcinomas and their matched normals.

  GynecologicMSK studiesSource code lgsocPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.